Table 5.
Survival analysis in myositis-associated RP-ILD (Cox proportional hazards model).
| Variables | Hazard ratio | 95% CI | P-value |
|---|---|---|---|
| UNIVARIATE | |||
| Fever | 2.823 | 0.730–10.918 | 0.133 |
| Skin ulceration | 3.726 | 1.554–8.932 | 0.003* |
| Subcutaneous/mediastinal emphysema | 2.999 | 0.721–12.475 | 0.131 |
| LDH > 245 U/L | 1.001 | 1–1.001 | 0.001* |
| AST > 40 U/L | 1.005 | 1.002–1.008 | 0.002* |
| Anti-Jo-1 antibody | 0.040 | 0–8.705 | 0.040* |
| Anti-MDA5 antibody | 11.320 | 1.450–88.356 | 0.021* |
| Lymphocytes in BALF <30% | 5.281 | 1.133–24.623 | 0.034* |
| MULTIVARIATE | |||
| Anti-MDA5 antibody | 11.639 | 1.338–101.240 | 0.026* |
| Lymphocytes in BALF <30% | 12.048 | 1.466–99.031 | 0.021* |
| Skin ulceration | 1.283 | 0.240–6.863 | 0.770 |
*
< 0.05. Initial predictors for poor survival of myositis-associated RP-ILD due to respiratory failure were verified by multivariate analysis. MDA5, melanoma differentiation-associated 5; RP-ILD, rapidly progressive interstitial lung disease; BALF, bronchoalveolar lavage fluid.